Publications (84) María Esperanza Rodríguez Ruiz publications

filter_list

2025

  1. 4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models

    Journal for immunotherapy of cancer, Vol. 13, Núm. 2

  2. Correction to: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours (Nature, (2025), 637, 8048, (1218-1227), 10.1038/s41586-024-08305-z)

    Nature

  3. Cross-priming in cancer immunology and immunotherapy

    Nature Reviews Cancer, Vol. 25, Núm. 4, pp. 249-273

  4. Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results

    Signal Transduction and Targeted Therapy, Vol. 10, Núm. 1

  5. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

    Nature, Vol. 637, Núm. 8048, pp. 1218-1227

  6. Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors

    CANCER RESEARCH COMMUNICATIONS, Vol. 5, Núm. 3, pp. 422-432

2024

  1. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

    Molecular Cancer, Vol. 23, Núm. 1

  2. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  3. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  4. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  5. NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma

    Journal for immunotherapy of cancer, Vol. 12, Núm. 8

  6. Radiotherapy protocols for mouse cancer model

    Methods in Cell Biology (Academic Press Inc.), pp. 99-113

  7. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701

2023

  1. A simple method to assess clonogenic survival of irradiated cancer cells

    Methods in Cell Biology, Vol. 174, pp. 127-136

  2. Flow cytometry-assisted quantification of immune cells infiltrating irradiated tumors in mice

    Methods in Cell Biology, Vol. 174, pp. 1-16

  3. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  4. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    OncoImmunology, Vol. 12, Núm. 1

  5. Methods to assess radiation induced abscopal responses in mice

    Methods in Cell Biology (Academic Press Inc.), pp. 81-92

  6. PSA reactivity in extracellular microvesicles to commercial immunoassays

    Clinica Chimica Acta, Vol. 543

  7. The Lymphatic Endothelium in the Context of Radioimmuno-Oncology

    Cancers, Vol. 15, Núm. 1